Project Grant HT94252510701

Award Date 7/1/25
Completion Date 6/30/27
Dollars Obligated $499K
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Houston, TX 77005, USA
Similar Awards
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $2,000,000.00 in funding to Tekhona Inc., a for-profit S corporation, to develop intra-articular immunoregulatory microparticles for inducing systemic remission in rheumatoid arthritis. The 2-year research project, with an award date of September 15, 2023 and an ultimate completion date of September 14, 2025, aims to transform healthcare for Service...
The U.S. Department of the Army Medical Command awarded a $4,324,139 project grant to Young Biopharma, LLC, a minority-owned biotech company located in Andover, MA. The grant, provided under the Military Medical Research and Development (CFDA 12.420) program, will fund the development of a novel TRP modulator, YB-16, to treat osteoarthritis knee pain. The project will run from June 15, 2025, to June 14, 2028. The Military Medical Research and Development program supports advanced biomedical...
This $818,337 federal Project Grant award, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research on extended limb stasis in the Encore Tissue Preservation Device. The research, conducted by Vascular Perfusion Solutions Inc., a self-certified small disadvantaged business located in San Antonio, TX, aims to advance medical solutions for military personnel and the broader public. The award, with a performance period from...
This federal Project Grant award in the amount of $749,343.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to New York University School of Medicine. The award is for a research project titled "P15-1 PEPTIDE TREATMENT FOR CARTILAGE INJURIES AND POST-TRAUMATIC OSTEOARTHRITIS" with a performance period from August 1, 2025 to July 31, 2027. The grant supports advanced biomedical research focused on transforming...
The Department of the Army Medical Command awarded Treventis Corporation a $2,977,166 Project Grant under the Military Medical Research and Development program (CFDA 12.420). The grant will fund the development of a small molecule anti-misfolding drug for frontotemporal degeneration from August 1, 2022 to July 31, 2025. The Military Medical Research and Development program supports biomedical research that transforms military and public health care through innovative solutions for battlefield...
The federal Project Grant award, totaling $6,663,794.00 and effective September 30, 2024, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports the "PRECISIE RTD TRIAL: PRECISION WITH RETURN-TO-DUTY DECISIONS IN THE MILITARY" research initiative, which aims to transform healthcare for military service members. The primary awardee, The Geneva Foundation, will conduct advanced biomedical research and...
This federal Project Grant award from the Defense Health Agency, under the Military Medical Research and Development (CFDA 12.420) program, provides $5,099,737.00 in funding to 149 Bio LLC, a for-profit organization based in Miami, Florida. The grant supports the development of a "MYELOID-TARGETED NOVEL THERAPEUTIC FOR GLOMERULAR DISEASES", with a project period from July 1, 2025 to June 30, 2029. The funded research aims to transform healthcare for military service members and the...
The Defense Health Agency awarded a $750,000 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to the Philadelphia Research And Education Foundation (PREF), a non-profit research organization, to develop tissue-engineered motor units with a preformed vascular network as an implantable composite tissue to augment neurovascular regeneration in volumetric muscle loss. The award period runs from July 15, 2024 to July 14, 2027. PREF has extensive experience...
The Department of the Army Medical Command awarded a $157,500 Project Grant to The Washington University under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from June 1, 2021 to May 31, 2022 to restore functional ARF tumor suppression in non-small cell lung carcinoma through the use of peptide mimics. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of transforming...
The federal Project Grant award of $1,214,375.00 from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), is funding a research project led by Yale University. The project is investigating the use of decoy-resistant IL-18 and immune checkpoint inhibitors in preclinical murine and ex vivo patient-derived models of renal cell carcinoma. The award began on September 15, 2024 and is set to conclude on September 14, 2028. The Military Medical Research...

This federal Project Grant award in the amount of $498,988.00 was provided by the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) to support Ridgeline Therapeutics LLC, a Houston-based biotech company. The award is funding preclinical research and development of novel small molecule therapies for conditions related to aging, metabolism, and muscle function, with a focus on preventing osteoarthritis and speeding recovery following traumatic joint injury in military and civilian populations. Specifically, the funding is supporting studies evaluating the efficacy of Ridgeline's lead compounds RT-001 and RT-002 in treating age-related muscle weakness, diabetes, obesity, and muscular dystrophies. The award has a performance period from July 1, 2025 to June 30, 2027.

Generated 7/8/25, 2:04 AM